Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Statistical Research and Consulting Centre, Pfizer Global Research and Development, Sandwich, Kent, UK. Andy.P.Grieve@Pfizer.Com
Understanding the dose-response is critical for successful drug development. We describe an adaptive design to efficiently learn about the dose-response and the ED95. A dynamic termination rule allows for early discontinuation either for efficacy or futility. The design was deployed in ASTIN, a phase II proof-of-concept trial of the neuroprotectant, neutrophil inhibitory factor (NIF), in acute stroke. We discuss the learning from this trial.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on